Geographic variation in the prevalence of stimulant medication use among children 5 to 14 years old: Results from a commercially insured US sample

Pediatrics

Volumn 111, Issue 2, 2003, Pages 237-243

  Cox, Emily R ^a   Motheral, Brenda R ^a   Henderson, Rochelle R ^a   Mager, Doug ^a  

^a Express Scripts   (United States)

Author keywords

Attention deficit hyperactivity disorder; Geographic variation; Pharmacoepidemiology; Stimulants

Indexed keywords

AMPHETAMINE; DEXAMPHETAMINE; METHYLPHENIDATE; PEMOLINE MAGNESIUM; PSYCHOSTIMULANT AGENT;

ADOLESCENT; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CHILDHOOD DISEASE; DRUG USE; FAMILY SIZE; FEMALE; GEOGRAPHIC DISTRIBUTION; HEALTH INSURANCE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOEPIDEMIOLOGY; PREVALENCE; PRIORITY JOURNAL; RACE DIFFERENCE; REGRESSION ANALYSIS; RURAL AREA; SEX DIFFERENCE; URBAN AREA;

ADOLESCENT; AGE FACTORS; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD, PRESCHOOL; HUMANS; INSURANCE, PHARMACEUTICAL SERVICES; LINEAR MODELS; LOGISTIC MODELS; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; PRESCRIPTIONS, DRUG; RURAL HEALTH SERVICES; SEX FACTORS; SOCIOECONOMIC FACTORS; UNITED STATES; URBAN HEALTH SERVICES;

EID: 0037312986     PISSN: 00314005     EISSN: None     Source Type: Journal    
DOI: 10.1542/peds.111.2.237     Document Type: Article

References (41)

1. Teitelbaum F, Martinez R, Parker A, et al. 2000 Drug Trend Report. Maryland Heights, MO: Express Scripts, Inc; 2001
2. Robison LM, Sclar DA, Skaer TL, Galin R. National trends in the prevalence of attention-deficit/hyperactivity disorder and the prescribing of methylphenidate among school-age children: 1990-1995. Clin Pediatr. 1999;38:209-217
3. Zito JM, Safer DJ, dosReis S, Magder LS, Gardner JF, Zarin DA. Psychotherapeutic medication patterns for youths with attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med. 1999;153:1257-1263
4. Safer DJ, Malever M. Stimulant treatment in Maryland public schools. Pediatrics. 2000;106:533-539
5. Wolraich ML, Lindgren S, Stromquist A, Milich R, Davis C, Watson D. Stimulant medication use by primary care physicians in the treatment of attention deficit hyperactivity disorder. Pediatrics. 1990;86:95-101
6. Zito JM, Safer DJ, dosReis S, Gardner JF, Boles M, Lynch F. Trends in the prescribing of psychotropic medications to preschoolers. JAMA. 2000; 283:1025-1030
7. Richters JE, Eugene AL, Jensen PS, et al. NIMH collaborative multisite multimodal treatment study of children with ADHD: I. Background and rationale. J Am Acad Child Adolesc Psychiatry. 1995;34:987-1000
8. Safer DJ, Zito JM, Fine EM. Increased methylphenidate usage for attention deficit disorder in the 1990s. Pediatrics. 1996;98:1084-1088
9. Wennberg J, Wennberg D. Practice variations and the use of prescription drugs. In: Dartmouth Atlas of Health Care in Michigan. Detroit, MI: Blue Cross, Blue Shield of Michigan and Blue Care Network. Available at: http://www.bcbsm.com/atlas/practice/shtml. Accessed February 2, 2001
10. Zito JM, Safer DJ, dosReis S, Magder LS, Riddle MA. Methylphenidate patterns among Medicaid youths. Psychopharmacol Bull. 1997;33:143-147
11. Rappley MD, Gardiner JC, Jetton JR, Houang RT. The use of methylphenidate in Michigan. Arch Pediatr Adolesc Med. 1995;149:675-679
12. Woodwell DA. National Ambulatory Medical Care Survey: 1998 Summary. Advance Data From Vital and Health Statistics, Report Number 315. Hyattsville, MD: National Center for Health Statistics; 2000
13. Hennekens CH, Buring JE. Epidemiology in Medicine. 1st ed. Boston, MA: Little, Brown and Company; 1987
14. Diehr P, Cain K, Connell F, Volinn E. What is too much variation: The null hypothesis in small-area analysis. Health Serv Res. 1990;24:741-771
15. McPherson K, Strong PM, Epstein A, Jones L. Regional variations in the use of common surgical procedures: within and between England and Wales, Canada and the United States of America. Soc Sci Med [A]. 1981;15(3 pt 1):273-288
16. Diez-Roux AV. Multilevel analysis in public health research. Annu Rev Public Health. 2000;21:171-192
17. LeFever GB, Dawson KV, Morrow AL. The extent of drug therapy for attention deficit-hyperactivity disorder among children in public schools. Am J Public Health. 1999;89:1359-1364
18. Geronimus AT, Bound J. Use of Census-based aggregate variables to proxy for socioeconomic group: Evidence from national samples. Am J Epidemiol. 1998;148:475-486
19. Tamblyn R, Lavoei G, Petrella L, Monette J. The use of prescription claims databases in pharmacoepidemiological research: the accuracy and comprehensiveness of the prescription claims database in Quebec. J Clin Epidemiol. 1995;48:999-1009
20. Kirking DM, Ammann MA, Harrington CA. Comparison of medical records and prescription claims files in documenting prescription medication therapy. J Pharmacoepidemiol. 1996;5:3-15
21. Safer DJ, Krager JM. A survey of medication treatment for hyperactive/inattentive students. JAMA. 1988;260:2256-2258
22. Jensen PS, Martin D, Cantwell DP. Comorbidity in ADHD: implications for research, practice, and DSM-V. J Am Acad Child Adolesc Psychiatry. 1997;36:1065-1079
23. Safer DJ, Krager JM. Hyperactivity and inattentiveness: school assessment of stimulant treatment. Clin Pediatr. 1989;28:216-221
24. American Academy of Pediatrics, Subcommittee on Attention-Deficit/Hyperactivity Disorder and Committee on Quality Improvement. Clinical practice guideline: treatment of the school-aged child with attention-deficit/hyperactivity disorder. Pediatrics. 2001;108:1033-1044
25. Goldman LS, Genel M, Bezman RJ, Slanetz P. Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. JAMA. 1998;279:1100-1107
26. Sherman M, Hertzig M. Prescribing practices of Ritalin: The Suffolk County, New York study. In: Greenhill L, Osman B, eds. Ritalin Theory and Management. New York, NY: Mary Ann Liebert Inc; 1991:187-193
27. Biederman J, Milberger S, Faraone S, et al. Family-environment risk factors for attention-deficit hyperactivity disorder: a test of Rutter's indicators of adversity. Arch Gen Psychiatry. 1995;52:464-470
28. Krager JM, Safer DJ. Type and prevalence of medication used in the treatment of hyperactive children. N Engl J Med. 1974;291:1118-1121
29. Krager JM, Safer D, Earhart J. Follow-up survey results of medication used to treat hyperactive school children. J Sch Health. 1979;49:317-321
30. Zito JM, Safer DJ, dosReis S, Riddle MA. Racial disparity in psychotropic medications prescribed for youths with Medicaid insurance in Maryland. J Am Acad Child Adolesc Psychiatry. 1998;37:179-184
31. Hoagwood K, Jensen PS, Feil M, Vitiello B, Bhatara VS. Medication management of stimulants in pediatric practice settings: a national perspective. J Dev Behav Pediatr. 2000;21:322-331
32. Bussing R, Schoenberg NE, Perwien AR. Knowledge and information about ADHD: evidence of cultural differences among African-American and white parents. Soc Sci Med. 1998;46:919-928
33. Bussing R, Zima BT, Perwien AR, Belin TR, Widawski M. Children in special education programs: Attention deficit hyperactivity disorder, use of services, and unmet needs. Am J Public Health. 1998;88:880-886
34. Biederman J, Faraone SV, Keenan K, et al. Further evidence for family-genetic risk factors in attention deficit hyperactivity disorder. Arch Gen Psychiatry. 1992;49:728-738
35. Eng HJ, Lairson DR. Prescribed medicines: Expenditure and usage patterns for selected demographic characteristics. J Pharm Marketing Management. 1988;3:19-36
36. Rabin DL. Use of medicines: A review of prescribed and nonprescribed medicine use. Med Care Rev. 1972;29:668-699
37. Motheral BR, Cox ER, Mager D, Henderson RR, Martinez R. Express Scripts Prescription Drug Atlas: A Study of Geographic Variation in the Use of Prescription Drugs, Maryland Heights, MO: Express Scripts, Inc; 2001
38. Wennberg JE, Barnes BA, Zubkoff M. Professional uncertainty and the problem of supplier-induced demand. Soc Sci Med. 1982;16:811-824
39. Chassin MR. Explaining geographic variations: the enthusiasm hypothesis. Med Care. 1993;31(suppl):YS37-YS44
40. Angold A, Erkanli A, Egger HL, Costello EJ. Stimulant treatment for children: a community perspective. J Am Acad Child Adolesc Psychiatry. 2000;39:975-984
41. Jensen PS, Kettle L, Roper MT, et al. Are stimulants overprescribed? Treatment of ADHD in four U. S. communities. J Am Acad Child Adolesc Psychiatry. 1999;38:797-804